Home LiteratureArticle Details
PMID: 3384955 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits.

The Journal of clinical investigation ·Vol. 81 ·No. 6 ·1988-06-00 ·Pages 1925-37

Mathison JC, Wolfson E, Ulevitch RJ

Abstract

Macrophages are induced by LPS to release a number of products that determine the host response during gram negative sepsis. To examine the role of one such substance, tumor necrosis factor (TNF), in mediating LPS-induced injury, we employed a rabbit model of endotoxic shock to (a) determine the kinetics and extent of release of TNF into plasma after injection of LPS, and (b) to evaluate the protective effect of in vivo neutralization of LPS-induced TNF by prior infusion of anti-TNF antibody. TNF was maximally induced 45-100 min after injection of 10 micrograms i.v. parent Salmonella minnesota Re595 LPS or 250 micrograms Re595 LPS-HDL complexes. Maximal induction of TNF by LPS was associated with development of hypotension, focal hepatic necrosis, intravascular fibrin deposition and lethality. Based on (a) the peak levels of TNF observed in serum, 2.5 X 10(3) U/ml, (b) the specific activity of purified rabbit macrophage-derived TNF, 1 X 10(8) U/mg, and (c) the biphasic disappearance of intravenously injected purified TNF (t1/2 = 0.5 min, 11 min) we constructed a kinetic model showing that at least 130 micrograms of TNF (1.3 X 10(7) U) was released into plasma 30-200 min postinjection of LPS. Prior infusion of anti-TNF antibody (30-45 min before LPS injection) resulted in neutralization of the LPS-induced serum TNF activity and provided significant protection from the development of hypotension, fibrin deposition, and lethality. Thus, these results provide further evidence that TNF plays a central role mediating the pathophysiologic changes that occur during gram negative endotoxic shock.

MeSH Terms
Animals Disease Models, Animal Gram-Negative Bacteria Half-Life Injections, Intravenous Kinetics Lipopolysaccharides/administration & dosage,toxicity Macrophages/metabolism Male Rabbits Shock, Septic/metabolism Tumor Necrosis Factor-alpha/blood,metabolism
Chemicals
Lipopolysaccharides Tumor Necrosis Factor-alpha
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Mathison J C
Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California 92037.
Wolfson E
Ulevitch R J
References (68)
68 references, click to expand
  1. In vivo interaction of bacterial lipopolysaccharide (LPS) with rabbit platelets: modulation by C3 and high density lipoproteins.
    J Immunol. 1981 Apr;126(4):1575-80 PMID: 7204977
  2. Sites of tissue binding and uptake in vivo of bacterial lipopolysaccharide-high density lipoprotein complexes: studies in the rat and squirrel monkey.
    J Clin Invest. 1981 Dec;68(6):1503-13 PMID: 7033286
  3. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.
    Biochem Biophys Res Commun. 1978 Feb 28;80(4):849-57 PMID: 637870
  4. The effect of complement depletion on bacterial lipopolysaccharide (LPS)-induced hemodynamic and hematologic changes in the Rhesus monkey.
    Am J Pathol. 1978 Jul;92(1):227-40 PMID: 99042
  5. The effects of bacterial endotoxins on host mediation systems. A review.
    Am J Pathol. 1978 Nov;93(2):526-618 PMID: 362943
  6. The modification of biophysical and endotoxic properties of bacterial lipopolysaccharides by serum.
    J Clin Invest. 1978 Dec;62(6):1313-24 PMID: 372234
  7. Silver staining of proteins in polyacrylamide gels.
    Anal Biochem. 1981 Nov 15;118(1):197-203 PMID: 6175245
  8. Biological activity, lipoprotein-binding behavior, and in vivo disposition of extracted and native forms of Salmonella typhimurium lipopolysaccharides.
    J Clin Invest. 1982 Oct;70(4):877-88 PMID: 6749904
  9. The fate of interleukin-2 after in vivo administration.
    J Immunol. 1983 May;130(5):2203-8 PMID: 6601147
  10. In vitro production of rabbit macrophage tumor cell cytotoxin.
    Int J Cancer. 1983 Jul 15;32(1):105-12 PMID: 6862689
  11. Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1.
    J Immunol. 1983 Sep;131(3):1160-6 PMID: 6604091
  12. Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s).
    J Immunol. 1983 Oct;131(4):1913-6 PMID: 6311900
  13. Pharmacokinetic study of partially pure gamma-interferon in cancer patients.
    Cancer Res. 1984 Sep;44(9):4164-71 PMID: 6430557
  14. VARCOV: a computer program for the distribution-free analysis of growth and response curves.
    Comput Programs Biomed. 1984;19(1):69-74 PMID: 6549282
  15. Human tumor necrosis factor. Production, purification, and characterization.
    J Biol Chem. 1985 Feb 25;260(4):2345-54 PMID: 3871770
  16. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.
    Science. 1985 Aug 30;229(4716):869-71 PMID: 3895437
  17. Purification and partial amino acid sequence of rabbit tumor necrosis factor.
    Int J Cancer. 1985 Sep 15;36(3):395-400 PMID: 4030139
  18. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin.
    Nature. 1985 Aug 8-14;316(6028):552-4 PMID: 2993897
  19. Human interleukin 1 is a cytocidal factor for several tumor cell lines.
    J Immunol. 1985 Dec;135(6):3962-8 PMID: 2415593
  20. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo.
    J Immunol. 1985 Dec;135(6):3972-7 PMID: 2999236
  21. Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor.
    Proc Natl Acad Sci U S A. 1985 Dec;82(24):8667-71 PMID: 3866246
  22. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin.
    Infect Immun. 1986 Mar;51(3):891-5 PMID: 3949385
  23. Modulation of endothelial cell hemostatic properties by tumor necrosis factor.
    J Exp Med. 1986 Mar 1;163(3):740-5 PMID: 3753996
  24. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.
    Am J Pathol. 1986 Apr;123(1):16-24 PMID: 2421578
  25. Stimulation of neutrophils by tumor necrosis factor.
    J Immunol. 1986 Jun 1;136(11):4220-5 PMID: 3009619
  26. Cachectin and tumour necrosis factor as two sides of the same biological coin.
    Nature. 1986 Apr 17-23;320(6063):584-8 PMID: 3010124
  27. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages.
    Biochem Biophys Res Commun. 1986 Apr 14;136(1):94-101 PMID: 3486658
  28. Molecular cloning and expression in Escherichia coli of the cDNA coding for rabbit tumor necrosis factor.
    DNA. 1986 Apr;5(2):149-56 PMID: 3519137
  29. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism.
    J Immunol. 1986 Jun 15;136(12):4548-53 PMID: 3486903
  30. Pharmacokinetics of murine tumor necrosis factor.
    J Immunopharmacol. 1986;8(1):89-97 PMID: 3711675
  31. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1.
    J Exp Med. 1986 Jun 1;163(6):1363-75 PMID: 3011946
  32. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
    J Exp Med. 1986 Jun 1;163(6):1433-50 PMID: 3486936
  33. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1.
    Proc Natl Acad Sci U S A. 1986 Jun;83(12):4533-7 PMID: 3487091
  34. Tumor necrosis factor provokes superoxide anion generation from neutrophils.
    Biochem Biophys Res Commun. 1986 Jun 30;137(3):1094-100 PMID: 3015137
  35. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum.
    J Exp Med. 1986 Sep 1;164(3):777-93 PMID: 2427635
  36. Tumour necrosis factor as immunomodulator and mediator of monocyte cytotoxicity induced by itself, gamma-interferon and interleukin-1.
    Nature. 1986 Sep 4-10;323(6083):86-9 PMID: 3092113
  37. Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor.
    J Exp Med. 1986 Oct 1;164(4):1350-5 PMID: 3020152
  38. Cachectin/tumor necrosis factor mediates changes of skeletal muscle plasma membrane potential.
    J Exp Med. 1986 Oct 1;164(4):1368-73 PMID: 3760781
  39. Shock and tissue injury induced by recombinant human cachectin.
    Science. 1986 Oct 24;234(4775):470-4 PMID: 3764421
  40. Raised serum levels of tumour necrosis factor in parasitic infections.
    Lancet. 1986 Dec 13;2(8520):1364-5 PMID: 2878227
  41. Detection of tumour necrosis factor-like cytotoxicity in serum from patients with septicaemia but not from untreated cancer patients.
    Scand J Immunol. 1986 Dec;24(6):739-43 PMID: 3798026
  42. Tumour necrosis factor is a compact trimer.
    FEBS Lett. 1987 Jan 26;211(2):179-84 PMID: 3803597
  43. Secretory products of macrophages.
    J Clin Invest. 1987 Feb;79(2):319-26 PMID: 3543052
  44. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
    J Immunol. 1987 Feb 1;138(3):963-74 PMID: 3805720
  45. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.
    Lancet. 1987 Feb 14;1(8529):355-7 PMID: 2880163
  46. Cachectin: more than a tumor necrosis factor.
    N Engl J Med. 1987 Feb 12;316(7):379-85 PMID: 3543677
  47. Production of lymphotoxin and tumour necrosis factor by a T-cell hybridoma.
    Immunology. 1987 Feb;60(2):213-7 PMID: 3102354
  48. Receptor binding and activation of polymorphonuclear neutrophils by tumor necrosis factor-alpha.
    J Leukoc Biol. 1987 Mar;41(3):196-204 PMID: 3031189
  49. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog.
    Surg Gynecol Obstet. 1987 May;164(5):415-22 PMID: 3576418
  50. The active form of tumor necrosis factor is a trimer.
    J Biol Chem. 1987 May 25;262(15):6951-4 PMID: 3034874
  51. Disparate effects of tumor necrosis factor-alpha/cachectin and tumor necrosis factor-beta/lymphotoxin on hematopoietic growth factor production and neutrophil adhesion molecule expression by cultured human endothelial cells.
    J Immunol. 1987 Jun 15;138(12):4298-302 PMID: 3495589
  52. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor.
    Nature. 1987 Jun 11-17;327(6122):524-6 PMID: 3495737
  53. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors.
    Proc Natl Acad Sci U S A. 1987 Jun;84(12):4273-7 PMID: 3108890
  54. Acute in vivo effects of human recombinant tumor necrosis factor.
    Lab Invest. 1987 Jun;56(6):583-90 PMID: 3599906
  55. Estimation of 3-deoxy sugars by means of the malonaldehyde-thiobarbituric acid reaction.
    Nature. 1960 Apr 9;186:155-6 PMID: 13813473
  56. PLATELET SEQUESTRATION IN MAN. I. METHODS.
    J Clin Invest. 1964 May;43:843-55 PMID: 14169513
  57. Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
    Nature. 1970 Aug 15;227(5259):680-5 PMID: 5432063
  58. Bacterial endotoxins. The second Carl Prausnitz Memorial Lecture.
    Int Arch Allergy Appl Immunol. 1975;49(1-2):1-43 PMID: 1095497
  59. Mediation systems in bacterial lipopolysaccharide-induced hypotension and disseminated intravascular coagulation. I. The role of complement.
    J Exp Med. 1975 Dec 1;142(6):1570-90 PMID: 1104750
  60. Significant contribution of spleen cells in mediating the lethal effects of endotoxin in vivo.
    Infect Immun. 1976 Sep;14(3):626-30 PMID: 965087
  61. Role of complement in lethal bacterial lipopolysaccharide-induced hypotensive and coagulative changes.
    Infect Immun. 1978 Jan;19(1):204-11 PMID: 24001
  62. Mechanisms of the hemodynamic effects of endotoxin.
    Physiol Rev. 1960 Apr;40:245-79 PMID: 13850016
  63. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits.
    J Immunol. 1979 Nov;123(5):2133-43 PMID: 489976
  64. Free Endotoxin.
    Nature. 1967 Jun 3;214(5092):1052 PMID: 4964234
  65. A new method for the extraction of R lipopolysaccharides.
    Eur J Biochem. 1969 Jun;9(2):245-9 PMID: 5804498
  66. New function for high density lipoproteins. Their participation in intravascular reactions of bacterial lipopolysaccharides.
    J Clin Invest. 1979 Nov;64(5):1516-24 PMID: 227936
  67. Interaction of lipopolysaccharides with plasma high-density lipoprotein in rats.
    Infect Immun. 1980 May;28(2):373-80 PMID: 7399668
  68. Purification and physico-chemical characterization of rabbit tumor necrosis factor.
    J Immunol. 1980 Oct;125(4):1671-7 PMID: 6997383
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
1988-06-00
Pages
1925-37
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC442645
Subset
IM
Grants
NIAID NIH HHS · AI-15136 · United States
NIGMS NIH HHS · GM 28485 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com